KYMR Latest News, Press Relases and Analysis

All

Press Releases

18 hours ago - By: Zacks Investment Research - Mentions: SNY GILD

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?

2 days ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

3 days ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

22 days ago - By: Benzinga

10 Analysts Have This To Say About Kymera Therapeutics

23 days ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

23 days ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

24 days ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

a month ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

a month ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

a month ago - By: Zacks Investment Research

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2 months ago - By: Zacks Investment Research - Mentions: GILD SNY

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

2 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

3 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

3 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

4 months ago - By: Zacks Investment Research - Mentions: CDXS

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: The Motley Fool - Mentions: GILD

Kymera Revenue Drops 55 Percent in Q2

4 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

4 months ago - By: Zacks Investment Research - Mentions: GSK GILD

GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up

4 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

5 months ago - By: Yahoo Finance - Mentions: MS PRMB

Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow

5 months ago - By: Yahoo Finance - Mentions: GILD

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

5 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

5 months ago - By: Yahoo Finance - Mentions: GILD MSFT SNY

Kymera weakness a buying opportunity, says Stifel

5 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Proposed Public Offering

5 months ago - By: Stocktwits - Mentions: GILD VTI UBS TSLA

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit

5 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

5 months ago - By: Gilead Sciences, Inc. - Mentions: GILD

KYMERA THERAPEUTICS INC (KYMR) Stock News

KYMR Latest News, Press Relases and Analysis

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

10 Analysts Have This To Say About Kymera Therapeutics

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

Earnings Scheduled For November 4, 2025

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

Kymera Revenue Drops 55 Percent in Q2

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Kymera weakness a buying opportunity, says Stifel

Kymera Therapeutics Announces Proposed Public Offering

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders